Print（PDF/122KB） Jul. 15, 2015 Licensing

Sumitomo Dainippon Pharma Announces Commercialization Partnership with Servier on Its Atypical Antipsychotic Agent Latuda (lurasidone hydrochloride) for Australia

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada) announced today that the Company has concluded a license agreement with Servier Laboratories (Aust) Pty Ltd. (Head office: Melbourne, Australia) ("Servier Australia"), the Australian subsidiary of Servier, relating to marketing, sales and distribution in Australia of LATUDA^® (lurasidone hydrochloride), an atypical antipsychotic agent created by Sumitomo Dainippon Pharma.

In March 2014, Sumitomo Dainippon Pharma obtained marketing approval for LATUDA^® from the Australian Therapeutic Goods Administration (TGA) for adult patients with schizophrenia.

This partnership with Servier Australia for the launch and commercialization of LATUDA^® in Australia is a further step forward to expand our LATUDA^® business. Sumitomo Dainippon Pharma plans to continue expanding the global presence of LATUDA^® as a treatment option for patients with schizophrenia.

Under the terms of the license agreement, Servier Australia will have the exclusive license to package, market, sell and distribute LATUDA^® in Australia and Sumitomo Dainippon Pharma will supply LATUDA^® bulk tablets to Servier Australia.

<Reference information>

About LATUDA^®:

LATUDA^® is an atypical antipsychotic developed originally by Sumitomo Dainippon Pharma, characterized by a unique chemical structure and an affinity for dopamine D2, serotonin 5-HT2A and serotonin 5-HT7 receptors where it has antagonist effects. In addition, LATUDA^® is a partial agonist at the serotonin 5-HT1A receptor and has no appreciable affinity for histamine or muscarinic receptors.
LATUDA^® has been available for the treatment of adults with schizophrenia in the United States since 2011, in Canada since 2012, in Switzerland since 2013, in Denmark, Norway and the U.K. since 2014, and in the Netherlands and in Finland since 2015. Sumitomo Dainippon Pharma is conducting Phase III clinical studies with a view to obtaining approvals of LATUDA^® for the treatment of schizophrenia in China and bipolar disorder in Japan. Similar efforts are ongoing in collaboration with Daiichi Sankyo Company, Limited for four Latin American countries and with Standard Chem. & Pharm. Co., Ltd. for Taiwan.

About Servier:

Servier is the first independent French research-based pharmaceutical company. Its development is driven by the pursuit of innovation in the therapeutic areas of cardiovascular, metabolic, central nervous system, psychiatric, bone, muscle and joint diseases, as well as cancer.
In 2014, the company recorded a turnover of 4 billion euros.
92% of Servier medicines are prescribed outside of France.
28% of turnover from Servier drugs was reinvested in Research and Development in 2014.
With a strong international presence in 146 countries, Servier employs more than 21,400 people worldwide.
More information is available at: www.servier.com

About Servier Australia:

Servier Australia is a member of the privately-held research-oriented global pharmaceuticals group Servier based in France. Servier Australia has its head office in Melbourne and its employment is over 150. With a main product line of therapeutics for clinical depression, hypertension and type-II diabetes, its total sales in 2014 amounted to about 100 million Australian dollars (about 9.6 billion yen).